Pilot trial evaluating once daily triple combination antiretroviral therapy with tenofovir-emtricitabine and efavirenz in HIV-1 infected patients with Mycobacterium tuberculosis infection ANRS129 BKVIR.

Trial Profile

Pilot trial evaluating once daily triple combination antiretroviral therapy with tenofovir-emtricitabine and efavirenz in HIV-1 infected patients with Mycobacterium tuberculosis infection ANRS129 BKVIR.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Dec 2015

At a glance

  • Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Efavirenz
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Dec 2015 Results published in the Journal of Antimicrobial Chemotherapy
    • 16 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top